Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI5752 in advanced solid tumors
NL-OMON60800Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of volrustomig in Nonhematologic neoplasms, sponsored by AstraZeneca. Primary endpoint: Primary endpoint(s). Started Aug 2020; status: completed.
02
Drugs
volrustomig
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60800.